Diversity in species composition and fungicide resistance profiles in Colletotrichum isolates from apples.

Outbreaks of bitter rot were observed in three commercial apple orchards in Illinois despite best management efforts during the 2018 production season. Three isolates from symptomatic fruit from these orchards and two isolates from an orchard in South Carolina were identified to the species level using morphological tools and calmodulin, glyceraldehyde-3-phosphate dehydrogenase, and beta-tubulin gene sequences. The isolates from Illinois were identified as Colletotrichum siamense of the Colletotrichum gloeosporioides species complex and the ones from South Carolina as Colletotrichum fioriniae and Colletotrichum fructicola of the Colletotrichum acutatum and the C. gloeosporioides species complex, respectively. Two of the three C. siamense isolates from Illinois were resistant to azoxystrobin and thiophanate-methyl as determined in mycelial growth tests in vitro. EC50 values were >100 µg/ml for both fungicides. One isolate was only resistant to azoxystrobin. None of the isolates from South Carolina was resistant to either of the two compounds. All five isolates were sensitive to fludioxonil (EC50 values <0.1 µg/ml), propiconazole (EC50 values ranged from 0.15 to 0.36 µg/ml), and benzovindiflupyr (EC50 values ranged from <0.1 to 0.33 µg/ml). Resistance in C. siamense to azoxystrobin and thiophanate-methyl was confirmed in detached fruit studies using apples treated with label rates of registered product. Resistance to thiophanate-methyl in C. siamense was based on E198A mutation in b-tubulin gene, whereas resistance to azoxystrobin was based on G143A in cytochrome b (CYTB). One isolate resistant to azoxystrobin possessed no amino acid variation in CYTB. This study shows that quinone outside inhibitor fungicide resistance in Colletotrichum from apple has emerged and is being selected for in Illinois apple orchards by current spray strategies. Resistance monitoring may alert growers to potential threats, but the employment of molecular tools based on current knowledge of resistance mechanisms will provide incomplete results.

Disseminated granuloma annulare--treatment with fumaric acid esters.

BACKGROUND: The therapy of disseminated granuloma annulare has often limited success. Treatment of granuloma annulare with fumaric acid esters (FAE) has recently been reported to be effective in 2 patients. OBJECTIVES: To assess the efficacy of a systemic therapy with FAE in consecutive patients with disseminated granuloma annulare. METHODS: Eight patients with disseminated granuloma annulare were treated with FAE in tablet form according to the standard therapy regimen used in psoriasis. The colour and the elevation of the skin lesions were assessed by a visual analogue scale before and after therapy. RESULTS: Systemic therapy with FAE induced a significant clinical improvement in elevation and colour of skin lesions, with remission in 3 and partial remission in 4 patients. One patient remained unchanged. Side-effects associated with the therapy were seen in 6 patients. CONCLUSIONS: Systemic therapy with FAE can be effective in patients suffering from disseminated forms of granuloma annulare, but side-effects of FAE have to be taken into consideration.

MIA as a reliable tumor marker in the serum of patients with malignant melanoma.

BACKGROUND: Reports published in 1996 concerning the protein MIA proposed it as a useful tumor marker for patients suffering from malignant melanoma. Therefore we systematically started to measure MIA levels in patients with malignant melanoma. It was and still is questionable whether MIA in the serum of melanoma patients is a reliable tumor marker in terms of course of disease, therapy-monitoring and prognostic value. Previous studies have already confirmed the specifity of MIA as a tumor marker for malignant melanoma. MATERIALS AND METHODS: Using an ELISA- System, we examined over 830 blood samples of 326 melanoma patients. The cut-off was determined at 9.8 ng/ml. RESULTS: 5.6% (n = 17) of melanoma patients at stage I/II (n = 302) showed increased MIA levels, whereas at stage III/IV (n = 5/n = 19) high levels were found in 60.0% and 89.5% respectively. Patients at stage III/IV with MIA levels below the cut-off turned out to be the ones after metastatic surgery, irradiation or chemotherapy. None of these patients developed further metastases during follow-up, just as patients at stage I/II without increased MIA levels. After a distinct rise of MIA levels, metastases could be detected at the same time or shortly after. On the other hand we saw decreasing levels after or during therapy. CONCLUSION: Our data showed that MIA is a suitable serum marker to detect metastases and to monitor course and therapy of disease. The prognostic value (increased MIA levels at stage I/II), however, requires further investigation.

Application of the strange situation attachment paradigm to a neurologically impaired population.

Mother-infant attachment was studied in 24 mother/impaired infant dyads. The infants, from 12 to 26 months chronological age, manifested primary neurological impairment or undiagnosed delay in gross and fine motor development. Measures of general development and degree of child impairment significantly differentiated "classifiability" of attachment in the Ainsworth scheme; thus, the most severely impaired infants were rated "not classifiable." For those infants who were fully classifiable (80% of the sample), only 1 measure of general development or degree of impairment differentiated quality of attachment classification. Infants rated higher on a measure of social responsiveness were more likely to possess secure attachments than those receiving lower ratings on the measure.